Case Study: Worsening Symptoms While Receiving Interferon Therapy for Multiple Sclerosis
A patient presents for evaluation with painful spasms of the right arm and leg.
Multiple Sclerosis
Risk for Conversion of MS Varies With Different Therapies
Researchers conducted a cohort study with prospective data from 68 neurology centers in 21 countries, this included 1555 patients with relapse-remitting MS.
Stem Cell Transplant Slows Progression of Multiple Sclerosis
For patients with relapsing-remitting multiple sclerosis, nonmyeloablative hematopoietic stem cell transplantation is associated with prolonged time to disease progression compared with disease-modifying therapy.
Rituximab Beneficial in Secondary Progressive MS
For patients with secondary progressive multiple sclerosis, treatment with rituximab is associated with a significantly lower Expanded Disability Status Scale score and delayed progression, according to a new study.
Bafiertam Gets Tentative Approval for Relapsing Multiple Sclerosis
Bafiertam is a new fumarate bioequialent alternative to its prodrug, Tecfidera (dimethyl fumarate; Biogen).
Test Your Knowledge on Multiple Sclerosis
Clinical approaches to the management of multiple sclerosis have evolved, with significant advances realized over the past several years. Take this 10-question assessment to test your knowledge of current clinical practice guidelines and treatment modalities for this unpredictable and often debilitating disease.
Food Allergy Linked to Increased Multiple Sclerosis Activity
The researchers found that compared with patients in the NKA group, those in the food allergy group had a 1.38 times higher rate for cumulative number of attacks; in an adjusted analysis, this difference remained significant (relapse rate ratio, 1.27).
Betaseron Labeling Updated With New Safety Data on Pregnancy
Data on the risk of interferon beta-1b use in women who were planning to become pregnant or were pregnant were collected from prospective observational studies and the Betaseron pharmacovigilance database.
NDA for Novel Relapsing Multiple Sclerosis Oral Treatment Submitted
Alkermes has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for a novel oral fumarate in development to treat relapsing forms of multiple sclerosis (MS).
FDA: MS Drug Linked to Cases of Stroke, Blood Vessel Wall Tears
Sine the approval of Lemtrada in 2014, the Agency has identified 13 cases worldwide of ischemic and hemorrhagic stroke or arterial dissection that occurred shortly after the patient received Lemtrada.
